OXBT News Alert Oxygen Biotherapeutics (OXBT) 4.04 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oxygen Biotherapeutics (OXBT) 4.04 $OXBT

Tenax Therapeutics Announces First Quarter Fiscal Year 2015 Financial Results
Business Wire - Wed Sep 24, 7:00AM CDT
--- Initiated and enrolled first patients in Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016 -
TENX: 3.80 (-0.05), OXBT: 4.04 (+0.02)

Oxygen Biotherapeutics discloses change in name and ticker symbol
M2 - Wed Sep 17, 5:17AM CDT
Specialist pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) reported on Monday the receipt of shareholder's approval to change its name to Tenax Therapeutics with effect from 19 September 2014.
OXBT: 4.04 (+0.02)

Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics (NASDAQ: TENX)
Business Wire - Tue Sep 16, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company received shareholder approval to change the Company name to Tenax Therapeutics, Inc. The name change shall go into effect on Friday, September 19, 2014, and at market open the Company's common stock will trade on the NASDAQ Capital Market under its new ticker symbol "TENX".
OXBT: 4.04 (+0.02)

Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial
Business Wire - Thu Sep 11, 4:30PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company, with unanimous approval from the Board of Directors, has elected to stop the current Phase IIb trial for its Oxycyte drug candidate and consider strategic alternatives for the program moving forward. The company will review the data generated on the patients enrolled in the trial to date.
OXBT: 4.04 (+0.02)

Oxygen Biotherapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference
Business Wire - Thu Aug 07, 3:00PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that John Kelley, Chief Executive Officer, will present a company overview at the Wedbush 2014 Life Sciences Management Access Conference at Le Parker Meridien in New York on Wednesday, August 13, 2014, at 1:20 p.m. ET.
OXBT: 4.04 (+0.02)

Oxygen Biotherapeutics Announces Collaboration with Imperial College London to Accelerate Enrollment of LeoPARDS Trial
Business Wire - Wed Aug 06, 7:00AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced a collaboration with Imperial College London to provide supplemental funding to support the accelerated enrollment and completion of the ongoing LeoPARDS Trial (Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis) awarded by the Efficacy and Mechanism Evaluation (EME) Programme and funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Oxygen is also currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome (LCOS).
OXBT: 4.04 (+0.02)

Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
Business Wire - Tue Jul 29, 7:01AM CDT
--Activated sites for Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016
OXBT: 4.04 (+0.02)

Oxygen Biotherapeutics to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on July 29, 2014
Business Wire - Tue Jul 22, 7:32PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that the Company will host a conference call and live audio webcast on Tuesday, July 29, 2014, at 8:30 a.m. ET to report financial results for the fourth quarter and fiscal year ended April 30, 2014, and provide a corporate update.
OXBT: 4.04 (+0.02)

Recent Scientific Publications Highlight Potential Benefits of Levosimendan in Cardiac Surgery and Additional Critical Care Conditions
Business Wire - Wed Jul 09, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions.
OXBT: 4.04 (+0.02)

Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products to 2017
M2 - Mon Jun 30, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45fldn/blood_the) has announced the addition of the "Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products" report to their offering. The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products provides an analysis of all the key market segments involved in this industry, including products, equipment and testing. The global blood industry has experienced strong growth in recent years and although this brisk expansion will slow somewhat as products continue to mature and pricing pressures increase, growth will remain solid though 2017 as a result of aging populations in the U.S., Europe and Japan; ongoing technology advancements/new product introductions and indications; expansion of health coverage in the U.S. via health care reform; and continued strong promotion of blood donation by collection agencies. A variety of infectious agents can be present in blood, including viruses (e.g., HIV-1, hepatitis B and C, HTLV, West Nile virus), bacteria, protozoans, Chagas disease, Lyme Disease and prions (e.g., the agent of variant Crueutzfeldt-Jakob disease, which is the human form of mad cow disease). As of 2013, the main residual risk is due to hepatitis B virus - ranging from 10 in Spain to 1.6 per million donations in France and Germany although other conditions such as variant Creutzfeldt-Jakob disease (vCJD) or HIV may pose high risk in certain regions. Testing markets covered include: - Blood Banking and Plasmapheresis Testing - Blood Typing - Human Immunodeficiency Virus (HIV) Testing - Hepatitis A Virus Testing - Hepatitis B Virus Testing - Hepatitis C Virus Testing - Human T-Cell Leukemia Virus Testing - West Nile Virus Testing - Other Safety Testing Blood products covered in the report include: - Red Blood Cells (RBCs) - Immunoglobulins - Albumin - Other Plasma Products - Synthetic HBOC and PFC Agents - Recombinant Factors Blood equipment revenues and forecasts are provided for: - Blood Collection Equipment - Automated Blood Collection Equipment In addition to complete market data, including forecasts to 2017, the study reports: - Product demand estimates by region - Collection and transfusion estimates - High-blood-loss procedure estimates - Product pricing - Reimbursement rates - Epidemiology of key conditions requiring blood products - Products on the market and in development The report also profiles key companies in the industry, including: - AABB - Abbott Laboratories - America's Blood Centers - American Red Cross - Baxter International - Bio-Rad Laboratories - BioTime Inc. - Gen-Probe Inc. /Hologic - Fenwal/Fresenius Kabi - Grifols Biologicals, Inc. - Novartis Diagnostics - Novo Nordisk A/S - OPK BioTech - Oxygen Biotherapeutics - Perftoran - Roche - Sanguine Corp. For more information visit http://www.researchandmarkets.com/research/45fldn/blood_the
ABT: 45.70 (-0.02), OXBT: 4.04 (+0.02), NVO: 43.80 (+1.08), BAX: 74.45 (-0.04), HOLX: 26.89 (+0.10), NVS: 93.91 (+0.66)

Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Tue Mar 04, 7:01AM CST
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has been notified by the U.S. Food and Drug Administration (the "FDA" that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte(R). Lifting of the clinical hold clears the company to proceed with the clinical development program in the US. The FDA communicated this information to the company during a conference call with the FDA on Friday, February 28, 2014. Written confirmation of the FDA's decision is expected to be received within 30 days.
OXBT: 4.04 (+0.02), EMCI: 34.01 (+0.29)

Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
OXBT: 4.04 (+0.02)

Newly Published Cardiac Surgery Study Provides Further Evidence that Levosimendan Significantly Improves Post-operative Kidney Function.
Business Wire - Thu Feb 13, 7:00AM CST
Oxygen Biotherapeutics, Inc., ("OBI" (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that a recently published study in the Journal of Cardiothoracic and Vascular Anesthesia provides evidence that levosimendan provides significant renal benefits to patients undergoing mitral valve surgery. The study was a double blinded, randomized, controlled trial of 128 patients with low ejection fraction (EF<45%) undergoing mitral valve surgery. As the authors reference, patients with low ejection fraction undergoing mitral valve surgery are at risk for adverse outcomes, including a significant risk for acute kidney injury. A link to access "In Press" version of this publication is found here http://www.jcvaonline.com/article/S1053-0770(...9/fulltext
OXBT: 4.04 (+0.02)

Staffordshire University: University Relocation Decision is in Best Interests of Students
Business Wire - Thu Jan 30, 1:35AM CST
Staffordshire University has announced plans to deliver the majority of its courses from one main campus in Stoke-on-Trent.
OXBT: 4.04 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 133

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 91

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 68

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 110

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading

Top 5 Most Recently Viewed Articles

Epic Yoga Event by Real Essentials to Support Ovarian Cancer

Updated Category News Views 70

Real Essentials Teams Up for Ovarian Cancer Awareness To honor Ovarian Cancer Awareness Month, Real Essentials, a brand celebrated for its affordable yet high-quality apparel, partnered with Not These Ovaries, a nonprofit organization dedicated to ovarian cancer. Together, they created a unique yoga event that aimed to raise both awareness and funds for essential ovarian...

Continue Reading
MKDWELL Tech Inc. Posts H1 2024 Financial Results Drop

Updated Category News Views 115

MKDWELL Tech Inc. Financial Overview for 2024 MKDWELL Tech Inc. (NASDAQ: MKDW), a key player in the automotive electronics industry with operations in Mainland China and Taiwan, has provided an update on its financial status for the first half of the fiscal year. The latest results show a significant decline in revenue compared to the same period in the previous year....

Continue Reading
Northwest Pipe Company Strengthens Production with New Facility

Updated Category News Views 212

Northwest Pipe Company Enhances Production Capacity Northwest Pipe Company, renowned for its expertise in water-related infrastructure, has announced a significant upgrade to its production facilities. The company has recently inaugurated a new precast concrete pipe and manhole manufacturing plant aimed at addressing the rising demand in the region. With this strategic...

Continue Reading
Allient Inc. Posts Third Quarter Gains Driven by Initiatives

Updated Category News Views 99

Allient Inc. Announces Impressive Third Quarter Results Allient Inc. (NASDAQ: ALNT), a global leader in precision and specialty Motion, Controls and Power products, has announced significant financial results for its third quarter. Despite facing challenges in key industrial and vehicle markets, the company has demonstrated resilience through its operational improvements...

Continue Reading
Fulcrum Therapeutics Investor Event to Unveil PIONEER Findings

Updated Category News Views 191

Introduction to Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a pioneering biopharmaceutical company, is dedicated to enhancing the lives of individuals grappling with genetically defined rare diseases. Their primary focus is on developing innovative small molecules that target specific diseases at their root cause. This commitment drives their latest...

Continue Reading